Respicardia

The remedē System by Respicardia is the only FDA-approved implantable neurostimulator for moderate to severe central sleep apnea in adults with reduced cardiac function. Clinical studies demonstrated that the system restores a more normal breathing pattern during sleep and improves quality of life for patients at high risk due to heart failure and related cardiovascular conditions.

The system delivers electrical pulses to the phrenic nerve, stimulating the diaphragm and correcting abnormal breathing patterns characteristic of CSA. It has been shown in randomized international studies to be effective in reducing symptoms such as chronic fatigue and excessive daytime sleepiness.

As of April 2021, Respicardia was acquired by ZOLL Medical Corporation.

Pipeline breadth before acquisition was focused on a single commercial product—the remedē System—for CSA.

No evidence of additional clinical-stage programs beyond this core technology.